AbCellera Biologics Inc. (ABCL) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AbCellera Biologics Inc.
Sector
Healthcare
Industry
Biotechnology
Employees
562
First IPO Date
December 11, 2020
Key Executives
| Name | Title | Pay | Year Born |
| Carl Hansen | Chief Executive Officer, President & Chairperson | 931,152 | 1975 |
| Veronique Lecault | Chief Technology Officer & Director | 681,646 | 1985 |
| Tryn T. Stimart | Chief Legal Officer, Chief Compliance Officer, Corporate Secretary & Privacy Officer | 709,275 | 1970 |
| Andrew Booth | Chief Financial Officer | 726,811 | 1974 |
| Caitlin Webster CIPD | Director of Talent Development | 0 | N/A |
| Marcie Thiessen | Senior Director of Finance & Accounting | 0 | N/A |
| Andrew Knowles | Vice President of Operations | 0 | N/A |
| Martin Hogan | Senior Director of Strategic Finance & IR | 0 | N/A |
| Murray McCutcheon | Senior Vice President of Partnering | 0 | N/A |
| Tiffany Chiu | Vice President of Communications | 0 | N/A |
AD
Description
AbCellera Biologics Inc. specializes in pioneering an advanced platform for the discovery of antibodies. This comprehensive, AI-driven system meticulously explores and analyzes natural immune systems to identify antibodies suitable for the creation of new pharmaceutical drugs. As of December 31, 2021, the company had cultivated 156 discovery programs, ranging from completed to in-progress or under contract, in partnership with 36 entities. Notably, AbCellera maintains a crucial research collaboration and license agreement with Eli Lilly and Company. Founded in 2012, the firm is headquartered in Vancouver, Canada.
AD
